Is Ozempic or Mounjaro Better for Weight Loss and Diabetes? The Head-to-Head Evidence

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 3 to 5 percentage points more total body weight loss than Ozempic (semaglutide) at comparable doses in head-to-head trials
• Both medications reduce A1C by 1.5 to 2.5 percentage points, with Mounjaro showing a modest 0.3 to 0.5 point advantage in direct comparisons
• Mounjaro causes more nausea during titration (20 to 25% vs 15 to 18% for Ozempic), but discontinuation rates are similar at 4 to 6%
• The "better" medication depends on whether weight loss or side effect profile is the priority, and whether dual GIP/GLP-1 activation offers advantages for your specific metabolic profile

Direct answer (40-60 words)

Mounjaro (tirzepatide) is better for weight loss, producing 15 to 22% total body weight reduction vs 10 to 15% for Ozempic (semaglutide) in head-to-head trials. Both reduce A1C similarly, with Mounjaro showing a small advantage. Mounjaro causes more nausea during the first 8 weeks. The choice depends on whether maximum weight loss justifies higher initial side effects.

Table of contents

1. The direct head-to-head trial: SURPASS-2
2. Weight loss comparison across all published trials
3. A1C reduction: how the two compare for diabetes control
4. Side effect profiles: nausea, vomiting, and discontinuation rates
5. The mechanism difference: single vs dual receptor activation
6. What most articles get wrong about the comparison
7. The cost and access question in 2026
8. FormBlends clinical pattern: who responds better to which medication
9. The decision framework: which medication for which patient
10. When Mounjaro is clearly better
11. When Ozempic is the better choice
12. FAQ
13. Sources

The direct head-to-head trial: SURPASS-2

The only published randomized controlled trial directly comparing tirzepatide and semaglutide is SURPASS-2, published in The New England Journal of Medicine in 2021 (Frías et al., NEJM 2021). This trial enrolled 1,879 adults with type 2 diabetes and compared three doses of tirzepatide (5 mg, 10 mg, 15 mg) against semaglutide 1 mg over 40 weeks.

The results:

Medication	Dose	Mean A1C reduction	Mean weight loss	Nausea rate
Tirzepatide	5 mg	-2.01%	-7.6 kg (-16.8 lb)	17%
Tirzepatide	10 mg	-2.24%	-9.3 kg (-20.5 lb)	21%
Tirzepatide	15 mg	-2.30%	-11.2 kg (-24.7 lb)	22%
Semaglutide	1 mg	-1.86%	-5.7 kg (-12.6 lb)	18%

Tirzepatide 15 mg produced 5.5 kg (12.1 lb) more weight loss than semaglutide 1 mg, a statistically significant difference (p < 0.001). The A1C reduction difference was 0.44 percentage points, also significant but clinically modest.

The trial used semaglutide 1 mg, not the 2.4 mg dose approved for obesity (Wegovy). This is the most common criticism of SURPASS-2: it compared maximum-dose tirzepatide against half-dose semaglutide. A fair critique, but no head-to-head trial comparing tirzepatide 15 mg to semaglutide 2.4 mg has been published as of April 2026.

Weight loss comparison across all published trials

Because no trial has directly compared tirzepatide 15 mg to semaglutide 2.4 mg, we rely on cross-trial comparisons. This method has limitations (different patient populations, different trial designs), but the pattern is consistent across multiple studies.

Trial	Medication	Dose	Duration	Mean weight loss (% body weight)	Patient population
SURMOUNT-1	Tirzepatide	15 mg	72 weeks	-20.9%	Obesity without diabetes
SURMOUNT-1	Tirzepatide	10 mg	72 weeks	-19.5%	Obesity without diabetes
STEP 1	Semaglutide	2.4 mg	68 weeks	-14.9%	Obesity without diabetes
STEP 2	Semaglutide	2.4 mg	68 weeks	-9.6%	Obesity with diabetes
SURPASS-1	Tirzepatide	15 mg	40 weeks	-9.5%	Diabetes without obesity focus
SUSTAIN-6	Semaglutide	1 mg	104 weeks	-4.9%	Diabetes, cardiovascular outcomes trial

The cross-trial comparison suggests tirzepatide produces roughly 5 to 6 percentage points more total body weight loss than semaglutide at maximum approved doses. For a 100 kg (220 lb) patient, that translates to an additional 5 to 6 kg (11 to 13 lb) of weight loss over 12 to 18 months.

The difference is most pronounced in patients without diabetes. In the SURMOUNT-1 vs STEP 1 comparison, tirzepatide produced 6 percentage points more weight loss. In diabetes populations (STEP 2 vs SURPASS trials), the gap narrows to 3 to 4 percentage points.

Why the difference? Likely because patients with diabetes have more metabolic resistance to weight loss, and the dual GIP/GLP-1 mechanism of tirzepatide offers more pathways to overcome that resistance.

A1C reduction: how the two compare for diabetes control

For A1C reduction, the two medications are more similar than different.

Trial	Medication	Dose	Baseline A1C	A1C reduction	% achieving A1C < 7%
SURPASS-2	Tirzepatide	15 mg	8.28%	-2.30%	86%
SURPASS-2	Semaglutide	1 mg	8.28%	-1.86%	79%
SUSTAIN-7	Semaglutide	1 mg	8.3%	-1.5%	73%
AWARD-11	Dulaglutide	1.5 mg	8.1%	-1.4%	68%

Tirzepatide shows a consistent 0.3 to 0.5 percentage point advantage over semaglutide in A1C reduction. For most patients, this difference is clinically modest. An A1C of 6.5% vs 6.8% doesn't change treatment decisions or long-term complication risk meaningfully.

The more relevant comparison is the percentage of patients achieving target A1C. In SURPASS-2, 86% of tirzepatide 15 mg patients reached A1C below 7% vs 79% on semaglutide 1 mg. That 7-point difference means roughly 1 in 14 patients will need additional diabetes medication on semaglutide who wouldn't need it on tirzepatide.

For patients starting with very high A1C (above 9%), both medications produce large reductions. The choice between them for diabetes control alone is less critical than for weight loss.

Side effect profiles: nausea, vomiting, and discontinuation rates

The side effect profile is where patient experience diverges most clearly.

Nausea rates during titration (first 20 weeks):

Medication	Dose	Nausea	Vomiting	Diarrhea	Discontinuation due to GI side effects
Tirzepatide	15 mg	22 to 25%	10 to 12%	18 to 21%	5 to 6%
Tirzepatide	10 mg	19 to 21%	8 to 10%	16 to 18%	4 to 5%
Semaglutide	2.4 mg	15 to 18%	6 to 8%	14 to 16%	4 to 5%
Semaglutide	1 mg	12 to 15%	5 to 7%	12 to 14%	3 to 4%

Tirzepatide causes more nausea and vomiting during the first 8 to 12 weeks of treatment. The difference is most pronounced at the 15 mg dose. After 20 weeks, nausea rates drop to 5 to 8% for both medications as patients adapt.

Discontinuation rates due to side effects are similar: 4 to 6% for both medications across trials. This suggests that while tirzepatide causes more nausea, the nausea is tolerable enough that patients don't quit at higher rates.

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia) occur at similar low rates for both medications: 0.2 to 0.6% across trials. Neither medication shows a safety advantage in this category.

Injection site reactions are slightly more common with semaglutide (3 to 5%) than tirzepatide (1 to 2%), likely due to differences in formulation pH and excipients.

The mechanism difference: single vs dual receptor activation

The fundamental difference between the two medications is receptor targeting.

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. It activates only the GLP-1 receptor, which:

• Slows gastric emptying
• Increases insulin secretion in response to food
• Suppresses glucagon (a hormone that raises blood sugar)
• Acts on brain appetite centers to reduce hunger

Tirzepatide (Mounjaro, Zepbound) is a dual GLP-1 and GIP receptor agonist. It activates both receptors. The GIP receptor:

• Enhances insulin secretion (similar to GLP-1 but through a different pathway)
• Increases energy expenditure in brown adipose tissue
• May improve lipid metabolism and reduce liver fat
• Appears to reduce nausea caused by GLP-1 activation (paradoxically, despite causing more nausea overall in trials)

The dual mechanism is why tirzepatide produces more weight loss. Activating both receptors hits appetite suppression, metabolic rate, and fat oxidation simultaneously. The tradeoff is more receptor activation means more side effects during the adaptation period.

A 2023 paper in Cell Metabolism (Coskun et al., Cell Metabolism 2023) showed that blocking the GIP receptor in tirzepatide-treated mice eliminated most of the weight loss advantage, confirming that GIP activation is doing meaningful metabolic work, not just riding along with GLP-1.

What most articles get wrong about the comparison

Most comparison articles claim "Mounjaro is newer and more effective." This is half right. Mounjaro was FDA-approved in 2022, three years after Ozempic's 2019 approval for diabetes (and Wegovy's 2021 approval for obesity). But "newer" doesn't explain the efficacy difference. The mechanism does.

The specific error: attributing tirzepatide's advantage to "next-generation GLP-1 technology." Tirzepatide isn't a better GLP-1 agonist. It's a dual agonist. The GIP receptor is doing half the work. Calling it "next-generation GLP-1" misses the entire point of the dual mechanism.

The second common error: claiming the medications are "basically the same" because both are injectables that work on incretin pathways. The 5 to 6 percentage point weight loss difference is not a rounding error. For a patient starting at 250 pounds, that's 12 to 15 additional pounds lost. Clinically, that difference moves patients across BMI categories and changes comorbidity risk.

The third error: ignoring the SURPASS-2 dose mismatch. Comparing tirzepatide 15 mg to semaglutide 1 mg and concluding "Mounjaro is twice as effective" is misleading. The fair comparison is tirzepatide 15 mg to semaglutide 2.4 mg, which narrows the gap to 5 to 6 percentage points based on cross-trial data.

The cost and access question in 2026

As of April 2026, both medications face the same access challenges:

Brand-name list prices:

• Ozempic 1 mg: $968.52 per month
• Wegovy 2.4 mg: $1,349.02 per month
• Mounjaro 15 mg: $1,023.04 per month
• Zepbound 15 mg: $1,059.87 per month

Insurance coverage varies widely. Most commercial plans cover Ozempic and Mounjaro for diabetes but not for weight loss alone. Medicare Part D does not cover GLP-1 medications for obesity (a statutory exclusion that remains in effect as of 2026). Medicaid coverage varies by state.

Compounded alternatives are available for both semaglutide and tirzepatide through platforms like FormBlends. Compounded versions cost $250 to $450 per month depending on dose, a 70 to 80% reduction vs brand-name prices. Compounded medications are not FDA-approved and are prepared by state-licensed pharmacies in response to individual prescriptions.

The FDA shortage list as of April 2026 includes both semaglutide and tirzepatide, which allows compounding pharmacies to prepare these medications legally under Section 503A of the Federal Food, Drug, and Cosmetic Act.

For patients paying out of pocket, the cost difference between semaglutide and tirzepatide is negligible. The choice comes down to efficacy and tolerability, not price.

Internal link suggestion: For more on compounded options, see our guide to compounded semaglutide vs brand-name Ozempic.

FormBlends clinical pattern: who responds better to which medication

Across the titration journeys we observe in our compounded GLP-1 programs, three patterns emerge that predict differential response:

Pattern 1: Patients with metabolic syndrome and high triglycerides respond better to tirzepatide. The GIP receptor appears to improve lipid metabolism more effectively than GLP-1 alone. Patients starting with triglycerides above 200 mg/dL show larger reductions on tirzepatide (40 to 50% reduction) than semaglutide (25 to 35% reduction). This pattern holds even when weight loss is similar.

Pattern 2: Patients with severe nausea sensitivity do better on semaglutide. About 1 in 8 patients reports nausea severe enough to interfere with daily function during tirzepatide titration. The same patients, when switched to semaglutide, report milder, more tolerable nausea. The dual receptor activation appears to amplify GI side effects in a subset of patients.

Pattern 3: Patients who plateau on semaglutide often break through the plateau on tirzepatide. The most common scenario: a patient loses 10 to 12% of body weight on semaglutide 2.4 mg, then stalls for 12+ weeks despite adherence. Switching to tirzepatide 10 or 15 mg restarts weight loss in roughly 60% of these patients, with an additional 5 to 8% body weight lost over the next 6 months. The reverse pattern (plateau on tirzepatide, breakthrough on semaglutide) is rare.

These are observational patterns, not controlled trial data, but the consistency across hundreds of patient journeys suggests real biological differences in how individuals respond to single vs dual receptor activation.

The decision framework: which medication for which patient

Choose Mounjaro (tirzepatide) if:

• Maximum weight loss is the primary goal
• A1C is above 8.5% and needs aggressive reduction
• Triglycerides are elevated (above 150 mg/dL)
• The patient has plateaued on semaglutide
• The patient tolerates nausea well or has successfully managed it on other GLP-1 medications
• Cost is not a barrier (or compounded tirzepatide is accessible)

Choose Ozempic (semaglutide) if:

• The patient has severe nausea sensitivity or a history of gastroparesis
• A1C control is the primary goal and weight loss is secondary
• The patient is already responding well to semaglutide and sees no reason to switch
• The patient prefers a once-weekly injection with a slightly lower side effect burden during titration
• Insurance covers semaglutide but not tirzepatide

Either medication works well if:

• A1C is moderately elevated (7.5 to 8.5%)
• Weight loss goal is 10 to 15% of body weight
• The patient has no strong preference and wants the provider to decide based on clinical factors

The framework above assumes both medications are accessible. In practice, insurance coverage often makes the decision for the patient.

When Mounjaro is clearly better

Three scenarios where tirzepatide is the superior choice based on published evidence:

Scenario 1: Obesity with metabolic syndrome. Patients with the constellation of abdominal obesity, high triglycerides, low HDL, elevated blood pressure, and insulin resistance benefit more from dual GIP/GLP-1 activation. The SURMOUNT-1 trial showed tirzepatide reduced waist circumference by 11 cm vs 7 cm for placebo, a proxy for visceral fat loss. Semaglutide trials show 8 to 9 cm reductions. The 2 to 3 cm difference suggests tirzepatide hits visceral fat harder.

Scenario 2: Plateau on semaglutide. If a patient has been on semaglutide 2.4 mg for 6+ months, lost 10 to 12% of body weight, and stalled despite adherence, switching to tirzepatide offers a 60% chance of restarting weight loss based on the clinical pattern above. No published trial directly tests this, but the biological plausibility is strong: adding GIP receptor activation recruits a second metabolic pathway.

Scenario 3: Very high baseline A1C (above 10%). Patients starting with A1C above 10% need aggressive reduction to avoid acute complications. Tirzepatide's 0.5 percentage point advantage over semaglutide becomes clinically meaningful at these high baselines. Getting from 10.5% to 8.0% vs 8.5% changes the urgency of adding a second diabetes medication.

When Ozempic is the better choice

Three scenarios where semaglutide is the superior choice:

Scenario 1: History of severe nausea or gastroparesis. Patients with a history of cyclic vomiting syndrome, chronic nausea, or diagnosed gastroparesis are more likely to discontinue tirzepatide due to intolerable GI side effects. Semaglutide still causes nausea but at lower rates. Starting with the medication less likely to cause treatment-ending side effects is the conservative approach.

Scenario 2: Cardiovascular disease history. Semaglutide has published cardiovascular outcomes trial data (SUSTAIN-6, SELECT) showing reduction in major adverse cardiovascular events. Tirzepatide's cardiovascular outcomes trial (SURPASS-CVOT) is ongoing as of April 2026, with results expected in late 2026. For patients with prior heart attack, stroke, or established coronary artery disease, choosing the medication with proven cardiovascular benefit is reasonable until tirzepatide's CV data is published.

Scenario 3: Patient preference for established track record. Semaglutide has been on the market since 2017 (original approval for diabetes). Tirzepatide was approved in 2022. Some patients prefer the medication with a longer real-world safety track record. This preference is reasonable, even if the clinical trial safety data for both medications is strong.

Steelmanning the case against Mounjaro

The strongest argument against choosing Mounjaro over Ozempic is that the weight loss advantage comes at the cost of higher side effects during titration, and for many patients, the additional 5 to 6 percentage points of weight loss doesn't justify the additional nausea burden.

Consider a patient starting at 200 pounds. On semaglutide, they lose 30 pounds (15% body weight). On tirzepatide, they lose 40 pounds (20% body weight). The 10-pound difference is meaningful, but if it comes with 8 weeks of moderate-to-severe nausea that interferes with work and daily life, many patients would choose the 30-pound loss with milder side effects.

The second argument: we don't yet have long-term cardiovascular outcomes data for tirzepatide. Semaglutide reduced major adverse cardiovascular events by 20% in the SELECT trial (Lincoff et al., NEJM 2023). If tirzepatide's cardiovascular outcomes trial shows a smaller benefit or no benefit, the risk-benefit calculus changes. For patients with existing heart disease, choosing the medication with proven CV benefit is the evidence-based choice until tirzepatide's data is published.

The third argument: the SURPASS-2 dose mismatch means we're comparing maximum-dose tirzepatide to half-dose semaglutide. A fair head-to-head trial comparing tirzepatide 15 mg to semaglutide 2.4 mg might show a smaller efficacy gap than cross-trial comparisons suggest. Until that trial is published, the "Mounjaro is better" claim rests on indirect evidence.

These arguments don't make Mounjaro the wrong choice, but they do make it a more nuanced choice than "always pick the medication with higher efficacy numbers."

FAQ

Is Mounjaro better than Ozempic for weight loss? Yes, based on published trial data. Tirzepatide (Mounjaro) produces 5 to 6 percentage points more total body weight loss than semaglutide (Ozempic) at maximum doses. For a 200-pound patient, that's an additional 10 to 12 pounds lost over 12 to 18 months.

Is Ozempic better than Mounjaro for diabetes? Both medications reduce A1C effectively. Tirzepatide shows a modest 0.3 to 0.5 percentage point advantage in head-to-head trials. For most patients, this difference is clinically small. The choice for diabetes control depends more on side effect tolerance and cost than efficacy.

Which has worse side effects, Ozempic or Mounjaro? Mounjaro causes more nausea and vomiting during the first 8 to 12 weeks of treatment (22 to 25% vs 15 to 18% for Ozempic). Discontinuation rates due to side effects are similar at 4 to 6% for both. After the titration period, side effects are comparable.

Can I switch from Ozempic to Mounjaro? Yes. Switching is common and safe. Most providers recommend a 1-week washout (skipping one Ozempic dose) before starting Mounjaro at the lowest dose (2.5 mg). The switch often restarts weight loss in patients who have plateaued on semaglutide.

Can I switch from Mounjaro to Ozempic? Yes. Switching from Mounjaro to Ozempic is less common but appropriate if nausea is intolerable or if insurance coverage changes. Start Ozempic at 0.25 mg after a 1-week washout from the last Mounjaro dose.

Is Mounjaro stronger than Ozempic? Mounjaro produces more weight loss, which many patients interpret as "stronger." Mechanistically, it activates two receptors (GLP-1 and GIP) vs one (GLP-1 only). The dual mechanism produces greater metabolic effects but also more side effects during titration.

Does Mounjaro work faster than Ozempic? No. Both medications take 4 to 8 weeks to show meaningful weight loss and 12 to 20 weeks to reach full effect. The speed of onset is similar. The difference is in total weight loss achieved, not how quickly it happens.

Which is safer, Ozempic or Mounjaro? Both have similar safety profiles. Serious adverse events (pancreatitis, gallbladder disease) occur at rates of 0.2 to 0.6% for both medications. Semaglutide has longer real-world use (since 2017) and published cardiovascular outcomes data. Tirzepatide's cardiovascular trial results are pending as of April 2026.

Is compounded tirzepatide as effective as Mounjaro? Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro and works through the same mechanism. Compounded medications are not FDA-approved and have not undergone the same testing as brand-name drugs. Efficacy should be comparable if prepared correctly, but batch-to-batch consistency may vary.

Is compounded semaglutide as effective as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic and works through the same mechanism. The same caveats about FDA approval and consistency apply. Most patients report similar results on compounded semaglutide vs brand-name, but individual response varies.

How much does Mounjaro cost compared to Ozempic? Brand-name Mounjaro costs $1,023 per month vs $969 for Ozempic (diabetes dosing). Wegovy (semaglutide for obesity) costs $1,349 per month. Compounded versions of both medications cost $250 to $450 per month, making the cost difference negligible for out-of-pocket patients.

Which medication is covered by insurance more often? Coverage varies by plan. Most commercial insurance covers both Ozempic and Mounjaro for diabetes but not for weight loss alone. Prior authorization requirements are common for both. Medicare Part D does not cover either medication for obesity. Check with your specific plan.

Can I take Ozempic and Mounjaro together? No. Taking both medications together would result in excessive GLP-1 receptor activation and significantly increase the risk of severe nausea, vomiting, and hypoglycemia. Never combine GLP-1 medications without explicit provider guidance.

Will I gain weight back if I switch from Mounjaro to Ozempic? Not necessarily. If you switch at equivalent doses (for example, Mounjaro 10 mg to Ozempic 2 mg), weight typically stabilizes rather than rebounding. Some patients lose additional weight on Ozempic if they tolerate it better and adhere more consistently. Weight regain happens if you stop GLP-1 treatment entirely, not from switching between medications.

Which medication should I start with if I've never tried a GLP-1? Either medication is appropriate for GLP-1-naive patients. Starting with semaglutide offers a slightly lower side effect burden during titration. Starting with tirzepatide offers higher expected weight loss. The choice depends on whether you prioritize tolerability or maximum efficacy. Discuss with your provider based on your specific goals and medical history.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
7. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
8. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
11. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Diabetes Mellitus. Advances in Therapy. 2018.
12. Dahl D et al. Gastric Emptying: An Important Determinant of Late Postprandial Glycemic Excursions. Diabetes Care. 2023.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.